Cardiorespiratory dysautonomia in post-COVID-19 condition : Manifestations, mechanisms and management
(2023) In Journal of Internal Medicine 294(5). p.548-562- Abstract
A significant proportion of COVID-19 patients experience debilitating symptoms for months after the acute infection. According to recent estimates, approximately one out of ten COVID-19 convalescents reports persistent health issues more than three months after initial recovery. This "post-COVID-19 condition" may include a large variety of symptoms from almost all domains and organs, and for some patients it may mean prolonged sick-leave, homestay, and strongly limited activities of daily life. In this narrative review, we focus on the symptoms and signs of post-COVID-19 condition in adults-particularly those associated with cardiovascular and respiratory systems, such as postural orthostatic tachycardia syndrome (POTS) or airway... (More)
A significant proportion of COVID-19 patients experience debilitating symptoms for months after the acute infection. According to recent estimates, approximately one out of ten COVID-19 convalescents reports persistent health issues more than three months after initial recovery. This "post-COVID-19 condition" may include a large variety of symptoms from almost all domains and organs, and for some patients it may mean prolonged sick-leave, homestay, and strongly limited activities of daily life. In this narrative review, we focus on the symptoms and signs of post-COVID-19 condition in adults-particularly those associated with cardiovascular and respiratory systems, such as postural orthostatic tachycardia syndrome (POTS) or airway disorders-and explore the evidence for chronic autonomic dysfunction as a potential underlying mechanism. The most plausible hypotheses regarding cellular and molecular mechanisms behind the wide spectrum of observed symptoms-such as lingering viruses, persistent inflammation, impairment in oxygen sensing systems and circulating antibodies directed to blood pressure regulatory components-are discussed. In addition, an overview of currently available pharmacological and non-pharmacological treatment options is presented. This article is protected by copyright. All rights reserved.
(Less)
- author
- Fedorowski, Artur LU ; Olsén, Monika Fagevik ; Nikesjö, Frida ; Janson, Christer ; Bruchfeld, Judith ; Lerm, Maria and Hedman, Kristofer
- organization
- publishing date
- 2023-05-14
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 294
- issue
- 5
- pages
- 548 - 562
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:37183186
- scopus:85161078798
- ISSN
- 1365-2796
- DOI
- 10.1111/joim.13652
- language
- English
- LU publication?
- yes
- additional info
- This article is protected by copyright. All rights reserved.
- id
- e2471ece-5d29-4b5b-9a49-a35ebe37b09f
- date added to LUP
- 2023-05-21 03:30:51
- date last changed
- 2024-04-05 19:31:30
@article{e2471ece-5d29-4b5b-9a49-a35ebe37b09f, abstract = {{<p>A significant proportion of COVID-19 patients experience debilitating symptoms for months after the acute infection. According to recent estimates, approximately one out of ten COVID-19 convalescents reports persistent health issues more than three months after initial recovery. This "post-COVID-19 condition" may include a large variety of symptoms from almost all domains and organs, and for some patients it may mean prolonged sick-leave, homestay, and strongly limited activities of daily life. In this narrative review, we focus on the symptoms and signs of post-COVID-19 condition in adults-particularly those associated with cardiovascular and respiratory systems, such as postural orthostatic tachycardia syndrome (POTS) or airway disorders-and explore the evidence for chronic autonomic dysfunction as a potential underlying mechanism. The most plausible hypotheses regarding cellular and molecular mechanisms behind the wide spectrum of observed symptoms-such as lingering viruses, persistent inflammation, impairment in oxygen sensing systems and circulating antibodies directed to blood pressure regulatory components-are discussed. In addition, an overview of currently available pharmacological and non-pharmacological treatment options is presented. This article is protected by copyright. All rights reserved.</p>}}, author = {{Fedorowski, Artur and Olsén, Monika Fagevik and Nikesjö, Frida and Janson, Christer and Bruchfeld, Judith and Lerm, Maria and Hedman, Kristofer}}, issn = {{1365-2796}}, language = {{eng}}, month = {{05}}, number = {{5}}, pages = {{548--562}}, publisher = {{Wiley-Blackwell}}, series = {{Journal of Internal Medicine}}, title = {{Cardiorespiratory dysautonomia in post-COVID-19 condition : Manifestations, mechanisms and management}}, url = {{http://dx.doi.org/10.1111/joim.13652}}, doi = {{10.1111/joim.13652}}, volume = {{294}}, year = {{2023}}, }